Eli Lilly and Company

πŸ‡ΊπŸ‡ΈNew York Stock Exchange

Articles

17
Show Summary
Show Bulletpoints
Detailed View
Somewhat Bullish +50

Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?

πŸ“ˆ LLY shares rose 6% in past 30 days.

🎯 Leerink raised target to $1,232 on June 25.

πŸ’Š Strong demand continues for Mounjaro and Zepbound.

🀝 Eli Lilly acquired Centessa Pharmaceuticals on June 24.

🧠 Deal targets neuroscience with orexin receptor agonists.

πŸ“ˆ Eli Lilly (LLY) shares have risen roughly 6% over the past 30 days.

🎯 Leerink analyst David Risinger raised the price target to $1,232 with an Outperform rating on June 25.

🎯 Berenberg analyst Kerry Holford increased the price target to $1,135 while maintaining a Hold rating on June 22.

πŸ’Š Strong demand continues for metabolic treatments Mounjaro and Zepbound.

🀝 Eli Lilly completed the acquisition of Centessa Pharmaceuticals on June 24.

🧠 The acquired company focuses on orexin receptor 2 agonists for narcolepsy and sleep disorders.

πŸ“ˆ Stock price jumped approximately 1.5% immediately following the Centessa deal announcement.

πŸ”¬ The acquisition signals a strategic push into neuroscience and sleep medicine sectors.

Bullish Signals
  • Shares gained 6% over past month.
  • Analysts raised price targets at Leerink and Berenberg.
  • Strong demand for Mounjaro and Zepbound supports growth.
  • Centessa acquisition expands neuroscience portfolio.
Bullish Signals
  • LLY shares have gained roughly 6% over the past month, indicating positive market sentiment.
  • Analyst price targets were raised by both Leerink and Berenberg, reflecting confidence in the stock's valuation.
  • Strong consumer demand for metabolic treatments Mounjaro and Zepbound supports revenue growth expectations.
  • The successful completion of the Centessa Pharmaceuticals acquisition expands Lilly's portfolio into high-potential neuroscience areas.
Somewhat Bullish +45

Eli Lilly: Exceptional Pipeline, Less Attractive Entry Point (Rating Downgrade)

πŸ“ˆ Lilly stock hit $1,207.59 high by mid-2026.

πŸ’Š Kisunla sales surged 490.5% to $124 million.

πŸš€ Rally driven by Mounjaro and retatrutide efficacy.

⚠️ Downgraded to Hold due to sluggish Omvoh demand.

πŸ’° Trades at 31.1x P/E, seen as unattractive entry.

πŸ“ˆ Eli Lilly stock reached a 52-week high of $1,207.59 by the end of the first half of 2026.

πŸ’Š First-quarter sales for Alzheimer's drug Kisunla hit $124 million, up 490.5% year-over-year.

πŸš€ The rally is driven by strong performance in Mounjaro and the unprecedented efficacy of retatrutide for severe obesity.

⚠️ Analyst Allka Research downgraded LLY to a Hold rating due to sluggish demand for Omvoh.

πŸ’° The stock trades at a non-GAAP forward P/E ratio of 31.1x, cited as an unattractive entry point.

πŸ“Š Technical indicators show the stock trading above the +2Οƒ band formed from the VWAP after a small pullback.

πŸ† LLY is identified as a favorite within the $190 billion GLP-1 drugs market sector.

Bullish Signals
  • Stock hit new 52-week high of $1,207.59.
  • Kisunla sales grew 490.5% to $124 million.
  • Pipeline drug retatrutide shows unprecedented efficacy.
  • Mounjaro and Kisunla drive strong recent rally.
  • Company leads $190 billion GLP-1 drugs market.
Risk Factors
  • Sluggish Omvoh demand drags performance.
  • Non-GAAP forward P/E of 31.1x is unattractive.
  • Analyst downgraded to Hold due to valuation.
Bullish Signals
  • LLY stock reached a new 52-week high of $1,207.59, indicating strong recent momentum.
  • Kisunla generated $124 million in first-quarter sales, reflecting a massive 490.5% year-over-year growth.
  • The company's pipeline includes retatrutide, which is showing unprecedented efficacy in treating severe obesity.
  • Existing drugs Mounjaro and Kisunla are delivering strong performance that supports the recent rally.
  • LLY remains a top-ranked favorite within the massive $190 billion GLP-1 drugs market.
Risk Factors
  • Demand for the drug Omvoh is described as sluggish, acting as a drag on overall performance.
  • The stock trades at a non-GAAP forward P/E ratio of 31.1x, which an analyst considers an unattractive entry point.
  • An analyst has officially downgraded the rating from a previous bullish stance to Hold due to valuation concerns.
Bullish +65

Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly

🀝 Eli Lilly partners with Abbisko on experimental medicines.

πŸ’° Deal includes up to $1.9 billion in potential payments.

πŸ“ˆ Abbisko shares rose 4% after partnership announcement.

πŸ”¬ Agreement covers discovery and early development programs.

🌍 Collaboration aims to bring new global treatment options.

🀝 Eli Lilly collaborates with Abbisko Therapeutics on experimental medicines across multiple therapeutic targets.

πŸ’° Abbisko Therapeutics receives an undisclosed upfront payment plus potential milestone payments totaling up to $1.9 billion.

πŸ“ˆ Abbisko Cayman shares rose approximately 4% following the announcement of the partnership.

πŸ”¬ The agreement covers discovery and early development activities for new drug programs.

🌍 Both companies aim to bring new treatment options to patients globally through this collaboration.

Bullish Signals
  • Abbisko secures up to $1.9 billion in milestone payments from Eli Lilly.
  • Eli Lilly partnership validates R&D capabilities and provides substantial capital resources.
Bullish Signals
  • Abbisko Therapeutics secures a significant potential deal value of up to $1.9 billion in milestone payments from Eli Lilly, indicating strong confidence in the pipeline's development and commercial potential.
  • The partnership with a major pharmaceutical giant like Eli Lilly validates Abbisko Therapeutics' R&D capabilities and provides substantial capital resources for advancing multiple drug programs.
Bullish +65

Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow - 24/7 Wall St.

πŸ“ˆ Lilly Q1 2026 revenue hit $19.8B, up 55.5%.

πŸ’Š Mounjaro sales surged 125%, contributing $8.66B.

πŸ“‰ Obesity drug prices fell 13% to boost volume.

βœ… FDA approved Foundayo, first oral GLP-1 without restrictions.

πŸš€ Pfizer acquired Metsera for $7B to add obesity assets.

πŸ“ˆ Eli Lilly reported Q1 2026 revenue of $19.80B, representing a 55.5% year-over-year increase.

πŸ’Š Mounjaro contributed $8.66B to Lilly's revenue, reflecting a 125% jump in sales.

πŸ“‰ Realized prices for Lilly's obesity drugs fell 13% as the company prioritizes volume growth and market share expansion.

πŸš€ Pfizer acquired Metsera for roughly $7B to integrate ultra-long-acting obesity assets into its pipeline.

πŸ’° Pfizer's revenue grew 5.4% to $14.45B, driven by Eliquis (+13%) and Padcev (+39%).

πŸ“‰ Pfizer saw significant declines in COVID products, with Comirnaty falling 59% and Paxlovid dropping 62%.

βœ… Lilly received FDA approval for Foundayo, the first oral GLP-1 pill without food or water restrictions.

⏳ Pfizer extended Vyndamax patent exclusivity to June 2031 via a settlement with US authorities.

πŸ“Š Analysts target a stock price of $1,215.79 for Eli Lilly based on its strong growth trajectory.

πŸ’Έ Pfizer offers a 6.61% dividend yield and trades at a forward PE ratio around 9.

Bullish Signals
  • Lilly revenue surged 55.5% to $19.80B.
  • Mounjaro sales jumped 125% to $8.66B.
  • Lilly volume increased 65% for market dominance.
  • Foundayo approved as first oral GLP-1 pill.
  • Analysts target Lilly at $1,215.79.
Risk Factors
  • Lilly prices fell 13% prioritizing volume over pricing power.
  • Pfizer COVID revenue down: Comirnaty -59%, Paxlovid -62%.
  • Lilly shares cooled 5.37% despite 40.92% one-year gain.
  • Pfizer's $7B Metsera deal needs successful Phase 3 data.
Bullish Signals
  • Lilly's revenue surged 55.5% to $19.80B, demonstrating exceptional growth in the obesity drug sector.
  • Mounjaro sales jumped 125% to $8.66B, solidifying Lilly's leadership in the GLP-1 market.
  • Lilly achieved a 65% volume increase while strategically accepting lower prices to secure market dominance.
  • Pfizer successfully extended Vyndamax patent exclusivity to June 2031, mitigating future revenue cliffs.
  • Lilly's Foundayo received FDA approval as the first oral GLP-1 pill without food or water restrictions.
  • Pfizer's Padcev sales surged 39%, contributing significantly to its overall revenue growth.
  • Analysts maintain a high price target of $1,215.79 for Lilly, reflecting confidence in its business model.
Risk Factors
  • Lilly's realized prices fell 13% as the company prioritizes volume over pricing power in the obesity market.
  • Pfizer faces a significant revenue decline in COVID-related products, with Comirnaty down 59% and Paxlovid down 62%.
  • Shares of Lilly cooled by 5.37% in the past week despite a 40.92% one-year gain, indicating stretched expectations.
  • Pfizer's $7B acquisition of Metsera requires successful Phase 3 data to justify the substantial spend.
Somewhat Bullish +45

Eli Lilly Stock (LLY) Opinions on Pipeline Expansions and Regulatory Risks - Quiver Quantitative

πŸ“ˆ Q1 2026 revenue surged 55.55% to $19.8 billion.

πŸ’° Acquired 4E Therapeutics to expand chronic pain portfolio.

⚠️ Inventory and receivables growth raise cash flow concerns.

πŸ“‰ Major institutions sold billions while others accumulated shares.

🎯 Analysts remain bullish with median price target of $1280.

πŸ“ˆ Eli Lilly reported Q1 2026 revenues of $19.8 billion, marking a significant 55.55% increase from the prior year.

πŸ’° The company recently acquired 4E Therapeutics to bolster its chronic pain management portfolio and complement existing oncology investments.

⚠️ Valuation concerns are rising due to rapid inventory growth and receivables that analysts fear could pressure free cash flow conversion.

πŸ“‰ Insider selling is aggressive, with Endowment Inc. alone selling 298,610 shares for approximately $329 million in the last six months.

πŸ›οΈ Major institutional investors like J. Stern & Co. and Capital International Investors have significantly reduced their positions by billions of dollars in Q1 2026.

πŸ“Š Conversely, some funds are accumulating shares, with Fifth Third Bancorp adding over $1.3 billion and Assenagon Asset Management adding $1.1 billion.

🌍 European regulatory developments are emerging as a potential headwind that could impact the company's international expansion plans.

🎯 Wall Street analysts maintain bullish ratings with a median price target of $1280, though individual targets range from $1183 to $1400.

πŸ”¬ Positive early data on acquired assets and long-term potential in metabolic therapies continue to fuel renewed bullish commentary.

πŸ“ Guggenheim issued a 'Buy' rating with a price target of $1183, while Barclays set a higher target of $1400.

Bullish Signals
  • Q1 2026 revenues surged to $19.8 billion with 55.55% growth.
  • Analysts maintain outperform ratings with a median price target of $1280.
  • Acquisition expands pipeline in chronic pain management and oncology.
  • Positive early data on acquired assets drives renewed bullish commentary.
  • Institutional buying persists from Fifth Third Bancorp (+$1.36B) and Assenagon.
Risk Factors
  • Valuation concerns over optimistic assumptions.
  • Inventory growth pressures free cash flow.
  • Insiders sold 298,610 shares for $329M.
  • Institutions removed billions in Q1 2026.
  • European regulations hinder expansion.
Bullish Signals
  • Q1 2026 revenues surged to $19.8 billion, reflecting a robust 55.55% year-over-year growth rate.
  • Analysts maintain outperform ratings with a median price target of $1280 and individual targets reaching as high as $1400 from Barclays.
  • The acquisition of 4E Therapeutics strategically expands the pipeline in chronic pain management, complementing strong oncology investments.
  • Positive early data on acquired assets is driving renewed bullish commentary despite broader market caution.
  • Long-term potential in metabolic therapies remains a key growth driver supporting current valuations.
  • Institutional buying persists from specific funds like Fifth Third Bancorp (+$1.36B) and Assenagon Asset Management (+$1.10B), indicating selective confidence.
Risk Factors
  • Valuation scrutiny is intensifying with concerns that current multiples may already reflect overly optimistic assumptions.
  • Rapid inventory growth and increasing receivables are flagged as potential red flags that could pressure free cash flow conversion.
  • Significant insider selling occurred, with Endowment Inc. selling 298,610 shares for $329 million in the last six months.
  • Major institutional investors including J. Stern & Co. and Capital International Investors removed billions of dollars from their portfolios in Q1 2026.
  • European regulatory developments are identified as a possible headwind that could hinder international expansion plans.
Somewhat Bullish +45

Claris Financial LLC Takes $1.01 Million Position in Eli Lilly and ...

πŸ“ˆ Claris Financial acquired $1,007,000 LLY position in Q4.

πŸ“Š Brighton Jones increased stake to 9,597 shares worth $7.4M.

πŸ“‰ HSBC cut target price from $1,070 to $850.

πŸ’° Q2 EPS of $8.55 beat estimates by $1.58.

πŸš€ Revenue grew 55.5% to $19.80 billion in Q2.

πŸ“ˆ Claris Financial LLC acquired a new position in LLY valued at approximately $1,007,000 during the fourth quarter.

πŸ“Š Brighton Jones LLC increased its stake by 22.0%, now holding 9,597 shares worth $7,409,000.

πŸ“‰ HSBC lowered its rating from 'hold' to 'reduce' and cut the target price from $1,070 to $850.

πŸ“ˆ Weiss Ratings downgraded LLY from a 'buy (b)' to a 'buy (b-)' rating in late May.

πŸ’° The company reported Q2 EPS of $8.55, beating analyst estimates of $6.97 by $1.58.

πŸ“ˆ Revenue for the quarter reached $19.80 billion, exceeding expectations of $17.82 billion.

πŸš€ Quarterly revenue grew 55.5% compared to the same period in the previous year.

🎯 The company provided FY 2026 EPS guidance between $35.50 and $37.00.

πŸ’΅ A quarterly dividend of $1.73 was paid on June 10th with an annualized yield of 0.6%.

πŸ“‰ The stock trades at a P/E ratio of 39.03 with a market capitalization of $1.03 trillion.

Bullish Signals
  • EPS beat expectations at $8.55 vs $6.97 estimate.
  • Revenue surged to $19.80 billion, beating estimates.
  • Quarterly revenue grew 55.5% year-over-year.
  • FY 2026 EPS guidance ranges from $35.50 to $37.00.
  • Stock rated Moderate Buy with $1,227.74 target price.
Risk Factors
  • HSBC downgraded stock to reduce with $850 target.
  • Weiss Ratings lowered rating from buy (b) to buy (b-).
  • Stock volatility ranges between $623.78 low and $1,182.73 high.
Bullish Signals
  • Eli Lilly significantly beat earnings expectations, reporting $8.55 EPS versus the consensus estimate of $6.97.
  • Revenue surged to $19.80 billion, surpassing analyst estimates of $17.82 billion by nearly $2 billion.
  • The company demonstrated robust growth with quarterly revenue increasing 55.5% year-over-year.
  • Management provided strong forward guidance for FY 2026, projecting EPS between $35.50 and $37.00.
  • Analysts anticipate the company will post approximately $35.80 EPS for the current year, aligning with or exceeding guidance.
  • The stock maintains a 'Moderate Buy' consensus rating from MarketBeat with an average target price of $1,227.74.
Risk Factors
  • HSBC downgraded the stock from 'hold' to 'reduce' and lowered its target price significantly to $850.
  • Weiss Ratings recently downgraded the stock from a 'buy (b)' to a slightly lower 'buy (b-)' rating.
  • The stock has experienced volatility, trading between a twelve-month low of $623.78 and a high of $1,182.73.
Bullish +65

FDA Approves New Eight-Week Maintenance Dosing Regimen for Eli Lilly’s (LLY) EBGLYSS

πŸ“… FDA approved 8-week maintenance dosing for EBGLYSS on June 9.

πŸ‘₯ Regimen covers adults and children 12+ with moderate-to-severe atopic dermatitis.

πŸ’‰ Single injection every 8 weeks replaces more frequent dosing schedules.

πŸ† Only treatment manageable with as few as six injections per year.

🚫 Maintenance no longer requires concomitant prescription topical medications.

πŸ“… FDA approved an eight-week maintenance dosing regimen for Eli Lilly's EBGLYSS on June 9.

πŸ‘₯ The new regimen applies to adults and children aged 12 and older with moderate-to-severe atopic dermatitis.

πŸ’‰ Patients can now receive a single injection once every 8 weeks instead of more frequent dosing.

πŸ† EBGLYSS becomes the only treatment option manageable with as few as six maintenance injections per year.

🚫 The new regimen does not require concomitant prescription topicals for maintenance.

πŸ“Š Approval is based on data from the Phase 3 ADjoin long-term extension trial covering 32 weeks.

βœ… Clinical data showed durable disease control without new safety signals or discontinuations due to adverse events.

πŸ›‘οΈ Common side effects remain consistent with the existing profile including conjunctivitis and injection site reactions.

πŸ‘©β€βš•οΈ Management noted the regimen reduces the burden of daily symptom management for patients.

πŸ’Š EBGLYSS is a human pharmaceutical product developed by Eli Lilly in the immunology space.

Bullish Signals
  • FDA approval simplifies treatment regimens.
  • Only atopic dermatitis treatment with six yearly injections.
  • Durable disease control confirmed over 32 weeks.
  • No discontinuations due to adverse events in long-term study.
  • Reduces burden of daily symptom management.
Bullish Signals
  • FDA approval of an extended dosing interval simplifies patient treatment regimens and improves convenience.
  • EBGLYSS becomes the only atopic dermatitis treatment requiring as few as six injections per year without topicals.
  • Long-term extension trial data confirms durable disease control over 32 weeks with no new safety signals.
  • No patients discontinued the drug due to adverse events in the long-term study, supporting its safety profile.
  • The regimen reduces the burden of daily symptom management and frequent injections for patients.
Bullish +65

Should You Buy Eli Lilly Stock Now or Wait for a Dip? - AOL.com

πŸ“ˆ Market cap hits $1 trillion driven by GLP-1 success.

πŸ’° Net income reaches $25.3 billion in trailing 12 months.

πŸ”¬ Expanding via acquisitions like Orna Therapeutics for RNA.

βš–οΈ Stock trades at premium 40x earnings valuation.

πŸ“‰ Shares delivered over 400% returns in last five years.

πŸ“ˆ Eli Lilly's market cap has reached $1 trillion, driven by strong performance in the GLP-1 weight loss market.

πŸ’° The company reported net income of $25.3 billion in the trailing 12 months, a significant increase from previous years.

πŸ”¬ Lilly is expanding its operations through strategic acquisitions, including Orna Therapeutics for RNA therapies and recent infectious disease portfolio additions.

βš–οΈ The stock currently trades at a premium valuation of 40 times its trailing earnings, which the article notes is not cheap.

πŸ“‰ Over the last five years, Eli Lilly shares have delivered returns exceeding 400% for investors.

🧬 The company is in the early innings of growth for its GLP-1 products Mounjaro and Zepbound, which are already generating billions in sales.

πŸ›‘οΈ Management is characterized as having a growth-oriented nature with a diverse operational portfolio supporting future expansion.

⏳ Analysts suggest that while the stock may fluctuate short-term due to market conditions, it remains an excellent long-term investment for five-plus year horizons.

πŸ“Š The article notes that Eli Lilly was excluded from The Motley Fool's recent top 10 Stock Advisor list, though the company maintains a bullish stance on its own prospects.

Bullish Signals
  • Market cap hit $1 trillion with 400% five-year returns.
  • Net income reached $25.3 billion in trailing 12 months.
  • Expanding pipeline via Orna Therapeutics and infectious disease deals.
  • GLP-1 products generate billions with massive future growth potential.
  • Deep financial pockets enable continued investment in growth.
  • Growth-oriented management focuses on long-term prospects.
Risk Factors
  • Premium valuation at 40x trailing earnings.
  • Potential short-term volatility from market conditions.
Bullish Signals
  • Eli Lilly has achieved a $1 trillion market cap and delivered over 400% returns over the past five years.
  • The company's net income reached $25.3 billion in the trailing 12 months, demonstrating massive profitability growth.
  • Lilly is successfully expanding its pipeline through acquisitions like Orna Therapeutics and recent infectious disease portfolio additions.
  • GLP-1 products Mounjaro and Zepbound are already generating billions in sales with significant future growth potential remaining.
  • The company possesses deep financial pockets that enable continued investment in future growth initiatives.
  • Management is described as growth-oriented, focusing on long-term prospects rather than short-term fluctuations.
Risk Factors
  • Eli Lilly trades at a premium valuation of 40 times trailing earnings, which the article explicitly describes as not cheap.
  • The stock faces potential short-term volatility due to broader market conditions and concerns regarding healthcare reform.
Bullish +60

Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

πŸ“ˆ Eli Lilly Q1 2026 revenue surged 55.5% with EPS guidance raised to $35.5-$37.

πŸ’Š Mounjaro revenue hit $8.66 billion, up 125%, while Zepbound added $4.16 billion.

πŸ“‰ Novo Nordisk sales fell 4% and plans to cut 9,000 jobs amid Ozempic decline.

πŸ’Š Foundayo FDA approved as only GLP-1 pill with no food or water restrictions.

πŸš€ Lilly acquired Orna, Centessa, Kelonia, and Ajax to expand cell therapy portfolios.

πŸ“ˆ Eli Lilly reported Q1 2026 revenue growth of 55.5% and raised non-GAAP EPS guidance to $35.5-$37.

πŸ’Š Mounjaro generated $8.66 billion in revenue, up 125% year over year, while Zepbound added $4.16 billion.

πŸ“‰ Novo Nordisk posted a 4% adjusted sales decline at constant currency and announced plans to cut 9,000 jobs.

πŸ’Š Foundayo received FDA approval as the only GLP-1 pill with no food or water restrictions.

πŸš€ Lilly announced acquisitions of Orna, Centessa, Kelonia, and Ajax to expand into cell therapy and other biology areas.

πŸ“‰ Novo's Ozempic sales slid 8% in the US, while Rybelsus dropped 15% globally.

πŸ’Š Novo's new Wegovy pill launched on January 5, 2026, booked $2.26 billion with over 1 million patients.

πŸ“‰ The CagriSema REDEFINE 4 trial missed its primary endpoint despite achieving 23% weight loss.

πŸ’Έ A planned 50% Wegovy list price cut in January 2027 is expected to pressure Novo's margins.

πŸ₯ Medicare Part D coverage for obesity drugs begins July 1, 2026, potentially offsetting future price cuts for Novo.

πŸ“ˆ Eli Lilly's stock has risen 48.98% over the past year reflecting bullish investor sentiment.

πŸ“‰ Novo Nordisk shares are down 41.53% over the past year and 14.22% year to date.

Bullish Signals
  • Revenue grew 55.5% in Q1 2026.
  • Mounjaro revenue surged 125% to $8.66 billion.
  • Zepbound revenue increased 80% to $4.16 billion.
  • International revenue climbed 81%.
  • Stock price rose 48.98% over the past year.
Risk Factors
  • Novo Nordisk adjusted sales declined 4% at constant currency.
  • Novo cutting 9,000 jobs due to declining sales.
  • Ozempic US sales fell 11%, Rybelsus dropped 15%.
  • CagriSema REDEFINE 4 trial missed primary endpoint.
  • Wegovy price cut in Jan 2027 pressures margins.
Bullish Signals
  • Eli Lilly grew revenue by 55.5% in Q1 2026, demonstrating strong momentum in its obesity franchise.
  • Lilly raised its non-GAAP EPS guidance to $35.5-$37, indicating confidence in future performance.
  • Mounjaro revenue surged 125% year over year to $8.66 billion, driven by international launches and China's NRDL inclusion.
  • Zepbound revenue increased 80% to $4.16 billion, showing robust growth in the weight-loss category.
  • Lilly successfully executed a volume-driven strategy with a 65% jump in volume despite lower realized prices.
  • Foundayo was approved by the FDA as the only GLP-1 pill without food or water restrictions, offering a unique market advantage.
  • Lilly's international revenue climbed 81%, suggesting significant global expansion potential.
  • Acquisitions in cell therapy and sleep-wake biology indicate a diversified growth strategy beyond current obesity drugs.
  • Ebglyss revenue jumped 141% and Jaypirka rose 79%, highlighting success in other therapeutic areas.
  • Lilly's stock price increased 48.98% over the past year, reflecting strong market confidence.
Risk Factors
  • Novo Nordisk reported a 4% adjusted sales decline at constant currency, signaling weakness in its core franchise.
  • Novo is cutting 9,000 jobs as part of a restructuring effort to address declining sales and portfolio fragmentation.
  • Ozempic US sales fell 11%, while Rybelsus dropped 15%, indicating challenges in the oral semaglutide segment.
  • The CagriSema REDEFINE 4 trial missed its primary endpoint, denting the next-generation drug thesis for Novo.
  • A planned 50% Wegovy list price cut in January 2027 will likely pressure Novo's gross margins significantly.
  • Novo Nordisk shares are down 41.53% over the past year and 14.22% year to date, reflecting investor concerns.
  • Lilly's high valuation means any stumble with Foundayo or other products could lead to a sharp stock correction.
Bullish +75

Eli Lilly is on pace for its first record close of 2026

πŸ“ˆ Shares rose 3.7% to trade near $1,123.

🎯 Stock on track for first 2026 record high.

πŸ’Š CVS restored Zepbound coverage, boosting investor sentiment.

πŸ“… Stock gained 22.3% year-to-date this strong month.

πŸ“ˆ Eli Lilly shares rose 3.7% on Thursday, trading near $1,123 per share.

🎯 If this price level holds, the company is on track for its first record closing stock price of 2026.

πŸ“‰ The previous record high was set on November 25 last year at $1,109.94 per share.

πŸ’Š CVS Health restored coverage for Eli Lilly's weight-loss drug Zepbound, boosting investor sentiment.

πŸ“… This rally adds to a strong month for the stock, which has gained approximately 22.3% year-to-date.

Risk Factors
  • Stock trades at $1,123, a premium over last year's record.
  • Shares up 22.3% MTD suggest gains driven by sentiment.
Risk Factors
  • Eli Lilly's stock is trading around $1,123, which represents a significant premium over the previous record close of $1,109.94 on Nov. 25 of last year, potentially indicating an unsustainable valuation.
  • The company's shares are up roughly 22.3% month to date, suggesting that recent gains may be driven by short-term sentiment rather than fundamental improvements in earnings or revenue growth.
Bullish +75

Cramer says Apple and Eli Lilly still have room to run after post-earnings rallies

πŸ“ˆ S&P 500 hit new highs driven by Apple's revenue beat and device record.

πŸ’° Eli Lilly surged 3% after reporting a massive 56% revenue jump.

⚠️ Cramer advises holding strong tech like Apple while avoiding premature Eli Lilly sales.

πŸ€– His trust follows strict delays: 45 minutes post-alert or 72 hours for TV mentions.

πŸ“ˆ The S&P 500 reached a new intraday high on Friday, driven primarily by strong gains in Apple shares.

πŸ’° Apple's second-quarter revenue rose 17% to $111.2 billion, surpassing analyst estimates of $109.7 billion.

πŸ”„ Jim Cramer described the market rally as "the comeback of the Mag Seven" following recent positive earnings from Amazon and Alphabet.

πŸ“± Apple reported an all-time high in its installed base of active devices across all categories and geographies, exceeding 2.5 billion units.

πŸ’¬ Cramer advised investors to "own" Apple stock rather than trade it after praising the company's earnings call as bringing him "pure joy".

⬆️ Shares of Eli Lilly rose another 3% on Friday following a significant post-earnings rally from Thursday's session.

πŸ§ͺ Eli Lilly reported an extraordinary quarter with revenue surging 56% year-over-year to $19.8 billion, beating top and bottom-line estimates.

⚠️ Cramer warned investors against selling Eli Lilly too soon despite the recent price increase, calling the move risky if executed now.

πŸ›οΈ The CNBC Investing Club is long on both Apple (APPL) and Eli Lilly (LLY), among other major tech and healthcare stocks.

πŸ€– Cramer's charitable trust follows a strict waiting period of 45 minutes after issuing trade alerts before executing any buy or sell orders.

πŸ“° If Cramer discusses a stock on CNBC TV, his trust waits an additional 72 hours after the alert before acting on it.

β›½ Oil prices fell on Friday as Iran reportedly shared an updated peace proposal to mediators in Pakistan.

πŸ•ŠοΈ Hope for a potential agreement between Iran and the US to end the war sparked the decline in energy commodity prices.

πŸ“… This recap covers key moments from Friday's "Morning Meeting" livestream held at 10:20 a.m. ET with Jim Cramer.

πŸ“‰ Meta and Microsoft reported earnings beats on Wednesday but failed to generate the same investor enthusiasm as Apple.

Bullish Signals
  • Eli Lilly saw an extraordinary quarter with revenue surging 56% year-over-year to $19.8 billion, representing massive top and bottom-line beats.
  • Shares of Eli Lilly jumped another 3% following a nearly 10% post-earnings rally, demonstrating continued strong investor confidence.
  • Jim Cramer emphasized that the stock has 'lots of room to run' and advised investors not to sell too soon, noting the exceptional performance.
  • The CNBC Investing Club holds positions in Eli Lilly (LLY), signaling bullish sentiment from Jim Cramer based on recent results.
Risk Factors
  • The article relies heavily on optimistic commentary from Jim Cramer regarding Apple and Eli Lilly without addressing any potential downside risks or valuation concerns.
  • Jim Cramer explicitly advises investors to 'own' Apple rather than 'trade it', which may discourage profit-taking in a potentially overvalued market after recent rallies.
  • Despite the positive earnings, Meta and Microsoft reported beats that failed to win over investors, indicating broader market skepticism towards Big Tech valuations.
  • The article includes standard investment disclaimers stating that no profit is guaranteed and no fiduciary duty exists, which serves as a risk warning for investors following Cramer's advice.
  • Cramer's charitable trust holds positions in several tech giants (GOOGL, META, MSFT) mentioned with mixed performance, suggesting concentration risk in the sector.
Somewhat Bearish -35

Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%

πŸ“‰ Novo Nordisk trades at a 12x earnings multiple versus Eli Lilly's 26x–38x valuation.

πŸ’Š Novo holds an early lead in oral GLP-1 uptake with over 18,000 recent prescriptions.

πŸ” Some analysts favor Novo as an income play or short-term catch-up opportunity over Lilly.

πŸ“‰ Novo Nordisk (NVO) has declined roughly 68% from its mid-2024 highs near $127, while Eli Lilly (LLY) continues to trade at a premium.

πŸ’Š Data suggests a prescription uptake gap for oral GLP-1s, with Novo's pill garnering over 18,000 prescriptions in the second week versus 3,700 for Lilly's newly approved Fendayo.

πŸ“Š Novo Nordisk trades at approximately 12x earnings compared to Eli Lilly's 26x to 38x valuation multiple, making it appear undervalued relative to its rival.

πŸ’° Novo is projected to offer a 4% dividend yield and a 6.5%+ free cash flow yield in 2027, which appeals to income-focused investors despite lower growth forecasts.

πŸ“ˆ Eli Lilly reported Q1 2026 revenue of $19.8 billion with EPS of $8.55, though management recently raised its full-year revenue guidance.

⚠️ Novo Nordisk has lowered its sales growth guidance for 2026 to a -5% to -13% range after recording 10% constant-currency growth in 2025.

πŸ”„ CNBC's Fast Money panel recently pivoted their stance, arguing that NVO now offers a more compelling setup than the GLP-1 category leader LLY.

πŸ’Έ The performance gap between the two has narrowed significantly, with LLY turning $1 into $2.30 over three years while NVO only reached $0.48 in the same period.

πŸ•°οΈ One panelist characterized Novo as a "get paid to wait" story for investors willing to endure near-term weakness for long-term dividends.

πŸ€” Some analysts view Novo's current opportunity as a short-term trade or catch-up play rather than a full-blown stock re-rating turnaround.

πŸ‘€ An expert analyst who correctly predicted NVIDIA in 2010 recently released his top 10 stocks for 2026, and notably excluded Eli Lilly from the list.

πŸ“‰ Current price performance shows NVO down 18.08% year-to-date while LLY is down 20.66%, creating similar absolute declines but different relative valuations.

Bullish Signals
  • Eli Lilly raised its full-year revenue guidance to a range of $82.0–$85.0 billion, signaling strong management confidence and execution.
  • Lilly's Q1 2026 revenue reached an impressive $19.80 billion with EPS of $8.55, demonstrating robust financial performance despite market headwinds.
  • CEO David Ricks characterized the approval of oral GLP-1 Fendayo as a "key milestone," highlighting significant progress in expanding their drug delivery options.
  • The company recently reported strong quarterly results that overshadowed concerns regarding early prescription uptake for its new oral pill.
  • With shares trading at approximately 26x earnings, Lilly maintains a premium valuation that reflects continued market dominance and strong growth expectations.
  • Over the past three years, Eli Lilly has outperformed peers significantly, turning $1 into $2.30, demonstrating superior long-term shareholder returns.
Risk Factors
  • Novo Nordisk's shares have fallen approximately 68% from its mid-2024 highs, dropping from near $127 to recent levels around $40.
  • Lilly's newly approved oral GLP-1 drug, Fendayo, received only 3,700 prescriptions in its second week compared to over 18,000 for Novo Nordisk's competing oral pill, indicating a significant uptake gap.
  • Novo Nordisk is guiding for -5% to -13% sales growth in 2026 after posting 10% constant-currency growth in 2025, signaling near-term headwinds.
  • Despite recent price action convergence where both stocks are down roughly 18-20%, Novo Nordisk trades at a discounted valuation of roughly 12x earnings versus Lilly's premium multiple closer to 38x-40x.
  • Lilly turned $1 into $2.30 over the past three years, while Novo fell to just $0.48 over the same period, creating a substantial gap in total shareholder return that investors are now questioning.
  • One panelist described the current view on Novo Nordisk as merely a 'trade' or short-term catch-up rather than a sustained re-rating, suggesting limited long-term upside potential.
Bullish +75

Eli Lilly stock soars after Q1 earnings as revenue grows 56% on strength of GLP-1 drug sales

πŸ“ˆ LLY stock surged nearly 10% after Q1 earnings exceeded expectations.

πŸ’Š GLP-1 sales jumped 56% year-over-year to $19.7 billion total.

βœ” FDA approval of Foundayo pill boosts weight-loss drug accessibility.

⚠ Shares remain down 13% YTD amid pricing and competition issues.

🩺 Mounjaro treats diabetes, while Zepbound focuses on weight management.

πŸ“ˆ Eli Lilly (LLY) stock surged nearly 10% on Thursday following the release of its Q1 earnings report.

πŸ’Š Revenue from GLP-1 drugs Zepbound and Mounjaro drove overall company revenue up 56% year over year to $19.7 billion.

πŸ”Ό Zepbound revenue jumped 80% to $4.16 billion, while Mounjaro sales soared 125% to $8.66 billion.

πŸ’° Despite price reductions in the US market, strong demand resulted in GLP-1s accounting for roughly two-thirds of total sales.

βœ”οΈ A major positive catalyst was the FDA approval of Foundayo, a new oral pill version of the weight-loss drug.

πŸ• The new Foundayo pill can be taken any time of day without food or water restrictions, according to CEO David Ricks.

⚠️ Despite the recent rally, LLY shares remain down approximately 13% year-to-date due to competition and pricing pressures.

🩺 Zepbound is approved for weight management, while Mounjaro is used for diabetes treatment.

Bullish Signals
  • Eli Lilly stock surged nearly 10% on strong earnings.
  • Revenue grew 56% year over year to $19.7 billion.
  • Zepbound revenue rose 80% despite lower US prices.
  • Mounjaro revenue soared 125% driven by robust demand.
  • GLP-1 drugs now account for roughly two-thirds of sales.
  • FDA approved Foundayo, the only unrestricted GLP-1 pill.
  • Foundayo approval boosts weight-loss business and product pipeline.
Risk Factors
  • Stock down 13% ytd due to competition and pricing pressure.
  • Heavy reliance on GLP-1s creates concentration risk at two-thirds of sales.
  • Lower US prices for Zepbound/Mounjaro indicate potential margin compression.
  • 80% and 125% growth in key drugs highlights segment vulnerability.
Bullish Signals
  • Eli Lilly (LLY) stock soared nearly 10% on Thursday following strong quarterly earnings.
  • Revenue grew 56% year over year to $19.7 billion, driven by robust demand for GLP-1 drugs Zepbound and Mounjaro.
  • Zepbound revenue increased 80% year over year to $4.16 billion despite lower US prices.
  • Mounjaro revenue soared 125% year over year to $8.66 billion as demand continues to lift overall sales.
  • GLP-1 drugs now account for roughly two-thirds of Eli Lilly's total sales, indicating a dominant market position.
  • The FDA approved Foundayo, the only approved GLP-1 pill that can be taken any time of day without food or water restrictions.
  • Foundayo approval provides a significant tailwind to the company's weight-loss business and product pipeline.
Risk Factors
  • Despite record-breaking revenue growth, Eli Lilly's stock is down roughly 13% year-to-date due to intensifying competition and pricing pressure.
  • The strong financial performance relies heavily on GLP-1 drugs which now account for approximately two-thirds of the company's total sales, creating significant concentration risk.
  • Lower prices for Zepbound and Mounjaro in the US market were required to achieve revenue growth, indicating potential margin compression from pricing headwinds.
  • Zepbound revenues increased 80% year over year to $4.16 billion while Mounjaro soared 125% to $8.66 billion, highlighting vulnerability to any future slowdown in this dominant segment.
Somewhat Bullish +50

Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill

πŸ“ˆ Amazon Pharmacy will stock Eli Lilly's GLP-1 pill Foundayo starting April 9, 2026.

πŸ’° LillyDirect prices Foundayo at $149/month lowest dose with Amazon dispensing support.

⚠️ Novo Nordisk faces competitive pressure as Wegovy shares Amazon kiosks with Foundayo.

πŸ“Š Lilly reported $11.67B Q4 2025 revenue from Zepbound and Mounjaro driving growth.

πŸš€ CVS Health benefits via Caremark insurance claims and retail pharmacy dispensing channels.

πŸ“ˆ Amazon Pharmacy will stock Eli Lilly's new GLP-1 pill Foundayo at One Medical kiosks starting April 9, 2026, with plans to expand to 4,500 locales by year-end.

πŸ’Š Foundayo is sold directly to patients through LillyDirect at $149 per month for the lowest dose, with Amazon acting as a key dispensing partner.

🏒 Eli Lilly stands as the clearest beneficiary due to direct revenue flow from Amazon Pharmacy filling prescriptions via the LillyDirect channel.

πŸ“‰ Novo Nordisk faces increased competitive pressure as its Wegovy pill now shares Amazon kiosks with Foundayo following recent market share losses.

πŸ’Ό CVS Health benefits across multiple arms including Caremark for insurance claims and retail pharmacies for dispensing existing scripts.

πŸš€ Viking Therapeutics stands to gain indirectly as a stronger GLP-1 market validates its pipeline asset VK2735 currently in Phase 3 trials.

πŸ“Š Lilly reported $11.67 billion combined revenue from Zepbound and Mounjaro in Q4 2025, driving full-year growth to $65.18 billion.

🀝 Amazon invested over $4 billion in 2025 to expand delivery options, with Foundayo's non-refrigerated pill format fitting the kiosk model.

πŸ’¬ Eli Lilly CEO David Ricks emphasized that deep pipelines and platforms like LillyDirect will expand their global health impact entering their 150th year.

🀝 Amazon CEO Andy Jassy highlighted a $200 billion capital expenditure expectation for 2026, positioning pharmacy within the broader thesis of faster customer reach.

⚠️ Novo Nordisk issued cautious 2026 guidance predicting adjusted sales growth between -5% and -13% due to pricing headwinds and competition.

🏭 Lilly is scaling manufacturing with a $6 billion facility in Alabama and a $3 billion oral medicine facility in Europe to support demand.

πŸ”¬ Viking Therapeutics CEO Brian Lian focused on clinical milestones rather than commercial distribution given its pre-revenue status.

πŸ’° Pharmacy sub-segment revenue for CVS grew 15.2% in Q4 2025 to $31.38 billion as same-store prescription volume accelerated by 9.7%.

🚚 Amazon's One Medical kiosk model is validated for future drug categories through every Foundayo prescription filled via the partnership.

Bullish Signals
  • Eli Lilly generated $11.67B quarterly revenue from Zepbound and Mounjaro in Q4 2025.
  • Full-year 2025 Eli Lilly revenue grew 44.7% to $65.18 billion.
  • Management raised full-year 2026 revenue guidance to $80-83 billion.
  • Eli Lilly invested in new $6B Alabama and $3B European manufacturing facilities.
  • Amazon Pharmacy serves nearly 100M customers with same-day delivery.
  • Amazon spent over $4 billion in 2025 on delivery options expansion.
  • Viking Therapeutics benefits from expanded GLP-1 market accessibility.
  • Novo Nordisk optimistic about US Wegovy pill launch in 2026.
Risk Factors
  • Novo Nordisk U.S. operations fell 15% in Q4 2025.
  • Novo Nordisk expects adjusted sales growth of βˆ’5% to βˆ’13% in 2026.
  • Viking Therapeutics lacks approved products and depends on future regulatory approval.
  • Lilly's manufacturing expansion requires $6B investment in Alabama.
  • Lilly's European facility requires $3B investment for oral medicine.
  • Amazon plans $200B capital expenditures in 2026, straining cash flow.
  • CVS revenue growth exposes it to Amazon competition risks.
  • LillyDirect sells at $149/month, limiting insurance coverage penetration.
Bullish Signals
  • Eli Lilly generated $11.67 billion in combined quarterly revenue from Zepbound ($4.26 billion) and Mounjaro ($7.41 billion) in Q4 2025, reflecting strong market uptake.
  • Full-year 2025 revenue for Eli Lilly reached $65.18 billion, representing a significant 44.7% year-over-year growth.
  • Management at Eli Lilly has raised full-year 2026 revenue guidance to a range of $80 billion to $83 billion, signaling strong confidence in future performance.
  • Lilly's manufacturing expansion includes major investments like a new $6 billion facility in Alabama and a $3 billion oral medicine facility in Europe to support global scale.
  • Amazon Pharmacy has expanded its reach to serve nearly 100 million customers with same-day delivery, creating deep recurring revenue opportunities through the healthcare channel.
  • Amazon invested over $4 billion in 2025 alone to triple its companywide delivery options, strengthening its healthcare integration strategy.
  • Viking Therapeutics sees indirect growth benefits as increased accessibility of GLP-1 drugs like Foundayo expands the total addressable market for its VK2735 pipeline.
  • Novo Nordisk expressed optimism about promising early uptake from the US launch of its Wegovy pill in 2026, despite broader market headwinds.
Risk Factors
  • Novo Nordisk's U.S. operations declined 15% in Q4 2025 due to lower realized prices and market share losses.
  • Novo Nordisk issued cautious 2026 guidance calling for adjusted sales growth of βˆ’5% to βˆ’13% at constant exchange rates amid intensifying competition.
  • Viking Therapeutics lacks both approved products and a direct Amazon Pharmacy relationship, relying entirely on future regulatory approval for revenue generation.
  • Lilly's manufacturing expansion requires significant capital allocation with $6 billion invested in an Alabama facility and $3 billion in a European oral medicine facility.
  • Amazon plans to invest approximately $200 billion in capital expenditures across the company in 2026, which may strain cash flow despite strong revenue growth.
  • Pharmacy sub-segment revenue growth of 15.2% for CVS reflects rising adoption but exposes the company to competitive pressures from Amazon's same-day delivery model.
  • Lilly's LillyDirect channel sells directly to cash-pay customers at $149 per month, potentially limiting payer relationships and insurance coverage penetration compared to injectables.
Bullish +75

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

πŸ“ˆ Lilly Q4 revenue surged 42.6% to $19.3B, driven by weight loss drugs.

πŸ’° Novo Nordisk Q4 revenue fell 7.6% amid pricing pressures and job cuts.

πŸ’Š Lilly's tirzepatide outperforms Novo's Wegovy with higher weight loss potential.

πŸ“ˆ Eli Lilly reported $19.29 billion in Q4 revenue, representing a 42.6% year-over-year increase driven primarily by its weight loss franchise.

πŸ’° Mounjaro generated $7.41 billion in Q4 with an 110% surge, while Zepbound contributed $4.26 billion and grew 123%.

πŸš€ Lilly’s tirzepatide is driving volume growth of 46% despite a slip in realized prices due to market conditions.

πŸ“‰ Novo Nordisk saw Q4 revenue decline by 7.6%, with U.S. operations specifically falling 15% year-over-year.

πŸ”¨ Novo cut approximately 9,000 jobs and incurred $8 billion in one-off charges during 2025 to address declining sales.

πŸ’‰ Novo’s Wegovy injectable offers roughly 14% body weight reduction compared to Lilly’s tirzepatide at 20%.

πŸ“ Novo launched an oral Wegovy pill in January 2026, generating around 50,000 weekly prescriptions across 70,000 pharmacies.

πŸ’Š Lilly’s oral candidate orforglipron submitted for approval in the U.S., Japan, and EU following Phase 3 data outperforming oral semaglutide.

🧬 Retatrutide, Lilly's triple agonist, demonstrated up to 71.2 lbs of weight loss during Phase 3 trials.

🏭 Lilly is expanding manufacturing capacity in Alabama, Pennsylvania, and Europe with over $50 billion in U.S. investment commitments.

⚠️ Novo faces structural pricing pressures from the Most Favoured Nations agreement and impending patent expiries.

🩺 Novo’s diabetes market share declined 3.6 percentage points to 30.1% as competitors gain ground.

πŸ’° Lilly trades at a 27x forward P/E multiple compared to Novo Nordisk's 11x forward earnings multiple.

πŸ“‰ Novo Nordisk saw its stock price decline 39.85% over the past year while Lilly gained 27.65%.

πŸ₯ A Medicare coverage expansion could add roughly 15 million eligible patients to the obesity drug market in 2026.

πŸ’‘ Novo’s CagriSema is submitted to the FDA for weight management, awaiting differentiated efficacy data.

πŸ“‰ Lilly’s pipeline depth and manufacturing scale provide a growth edge despite its higher premium valuation.

πŸ‘€ Market attention will focus on whether orforglipron approval by mid-2026 undercuts Novo's newly launched oral pill.

πŸ’Ό Novo Nordisk generates enormous cash flow but faces multi-year headwinds from pricing and patent dynamics.

🏦 Lilly trades at a 4x higher forward multiple, reflecting investors' confidence in its execution and growth trajectory.

πŸ“‰ Novo’s dividend yield stands at 4.88%, potentially appealing to value investors waiting for clinical or coverage catalysts.

Bullish Signals
  • Q4 revenue hit $19.29B, up 42.6% YoY driven by tirzepatide.
  • Mounjaro Q4 sales reached $7.41B (up 110%), Zepbound added $4.26B (up 123%).
  • Tirzepatide achieves ~20% weight loss, beating Novo's Wegovy (~14%).
  • Lilly expanding manufacturing across Alabama, Pennsylvania, and Europe.
  • Orforglipron approved in U.S., Japan, EU; beat oral semaglutide head-to-head.
  • Retatrutide lost up to 71.2 lbs in Phase 3 trials.
  • Orforglipron oral approval expected mid-2026 after beating oral semaglutide.
  • Lilly trades at 27x forward P/E, reflecting strong growth momentum.
  • Lilly up 27.65% vs. Novo down 39.85% over the past year.
Risk Factors
  • Revenue down 7.6% YoY; U.S. fell 15%.
  • Operating income slipped 0.53% amid cost pressures.
  • CEO warns of 2026 pricing headwinds in competition.
  • Cut 9,000 jobs; absorbed $8B charges in 2025.
  • Faces structural U.S. pricing pressure and patent expiry.
  • Diabetes market share down 3.6 points to 30.1%.
  • Stock down 39.85% YoY with forward P/E of 11x.
  • Competitor oral tirzepatide outperforms, threatening Novo's launch.
Bullish Signals
  • Liily's fourth quarter revenue reached $19.29 billion, representing a 42.6% year-over-year increase driven by its strong tirzepatide franchise.
  • Mounjaro generated $7.41 billion in Q4 (up 110%), while Zepbound added $4.26 billion (up 123%), demonstrating powerful growth from two core products.
  • Tirzepatide's dual GIP/GLP-1 mechanism delivers roughly 20% body weight reduction in trials, outperforming Novo's Wegovy at approximately 14%.
  • Lilly is building manufacturing at scale with new facilities in Alabama, Pennsylvania, and Europe, alongside commitments to exceed $50 billion in U.S. manufacturing investment since 2020.
  • Orforglipron has been submitted for approval in the U.S., Japan, and EU, with Phase 3 data showing it outperformed oral semaglutide in a head-to-head trial.
  • Retatrutide, a triple agonist developed by Lilly, showed weight loss of up to 71.2 lbs in Phase 3 trials, showcasing deep pipeline efficacy.
  • If Lilly receives orforglipron approval in the U.S. by mid-2026, it enters the oral market with a product that has already beaten oral semaglutide in a head-to-head trial.
  • Lilly trades at a 27x forward P/E, reflecting strong growth momentum and a business executing at a high level.
  • Lilly's one-year price gain of 27.65% reflects a business executing at a high level while Novo's 39.85% one-year decline reflects genuine structural concern.
Risk Factors
  • Novo Nordisk's fourth quarter revenue declined 7.6% year-over-year, with U.S. operations falling an even steeper 15%.
  • Operating income slipped 0.53% as costs tightened, indicating underlying profitability pressures despite full-year sales growth in DKK.
  • CEO Mike Doustdar warned that in 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market.
  • The company cut roughly 9,000 jobs and absorbed approximately $8 billion in one-off charges during 2025, signaling significant cost reduction efforts.
  • Novo faces structural pricing pressure from its Most Favoured Nations agreement with the U.S. administration and semaglutide patent expiry in select international markets.
  • The company's diabetes value market share declined 3.6 percentage points to 30.1%, reflecting competitive erosion in its core segment.
  • Novo Nordisk's stock is down 39.85% over the past year, with a forward P/E of 11x reflecting genuine structural concern compared to competitors.
  • Lilly's new oral tirzepatide (orforglipron) has already outperformed oral semaglutide in head-to-head trials, potentially putting Novo's oral Wegovy pill under immediate competitive pressure upon its January 2026 launch.
Bullish +75

Amazon expands access to weight-loss pill with kiosks, same-day delivery

πŸ’Š Amazon Pharmacy adds Eli Lilly's Foundayo GLP-1 pill to clinic kiosks by 2026.

πŸ“¦ No refrigeration needed for this oral weight-loss medication compared to injectable alternatives.

🚚 Same-day delivery expands in select areas with all prescriptions delivered within four days.

πŸ“¦ Amazon Pharmacy will stock Eli Lilly's new Foundayo GLP-1 pill at clinic kiosks starting in 2026.

πŸ’Š The oral medication offers storage advantages over injectable drugs by not requiring refrigeration.

🚚 Same-day delivery will be available in select areas, expanding beyond the current half of U.S. customers.

⏳ All prescription medications can be delivered within four days regardless of delivery speed tier.

🀝 Amazon Pharmacy is already filling prescriptions for Foundayo launched on Eli Lilly's direct-to-consumer platform.

πŸ₯ The rollout includes kiosks inside One Medical primary care clinics across selected locations.

πŸ“ Kiosk availability beyond California depends on state regulations and compliance requirements.

πŸ’΅ Prices for the lowest dose of Foundayo start at $149 per month for cash-paying customers via LillyDirect.

πŸ”™ Amazon began delivering oral Wegovy from Novo Nordisk earlier this year at select kiosks.

🚁 This initiative supports Amazon's broader multibillion-dollar investment to expand delivery in rural and underserved areas.

🌐 The strategy aims to improve access to common medications while reducing shipping costs through localized kiosk distribution.

Bullish Signals
  • Amazon expands access to Eli Lilly's Foundayo GLP-1 pill via One Medical kiosks and same-day delivery.
  • The pill requires no refrigeration, simplifying storage compared to injectable drugs.
  • Amazon will extend same-day medication delivery beyond its current half of U.S. customers.
  • All customers receive medication within four days through Amazon Pharmacy nationwide.
  • Amazon has delivered GLP-1 medications since 2021 and stocks Novo Nordisk's Wegovy at select kiosks.
  • Amazon Pharmacy fulfills LillyDirect prescriptions starting at $149/month for the lowest dose.
  • Amazon is investing multibillions to expand healthcare delivery in rural and underserved areas.
Risk Factors
  • Amazon's Eli Lilly drug deal faces regulatory scrutiny.
  • Kiosk model limited by state regulations outside California.
  • Same-day delivery serves only half of U.S. customers.
Bullish Signals
  • Amazon is expanding access to Eli Lilly's new GLP-1 weight-loss pill, Foundayo, by stocking it at clinics' One Medical kiosks and offering same-day delivery.
  • The pill does not require refrigeration, which simplifies storage and dispensing compared to injectable drugs and supports broader availability via kiosks.
  • Amazon plans to expand its same-day delivery reach for medications beyond the current half of U.S. customers it already serves.
  • All customers can receive medication within four days through Amazon Pharmacy, even in areas where same-day delivery isn't yet available.
  • Amazon has been delivering GLP-1 medications since 2021 and has begun stocking Novo Nordisk's oral Wegovy pill at select kiosks earlier this year.
  • Amazon Pharmacy fulfills prescriptions from Eli Lilly's direct-to-consumer platform, LillyDirect, making the medication accessible starting at $149 per month for the lowest dose.
  • The initiative is part of a multibillion-dollar investment by Amazon to expand its healthcare and delivery footprint, particularly in rural and underserved areas.
Risk Factors
  • Amazon's expansion into Eli Lilly's Foundayo drug may trigger regulatory scrutiny given the company's history with pharmaceuticals.
  • The kiosk model relies on state regulations that could restrict future expansion beyond California.
  • Same-day delivery remains limited to only half of U.S. customers, potentially reducing market penetration compared to competitors.
Neutral 0

Eli Lilly (LLY) Laps the Stock Market: Here's Why - Yahoo Finance

πŸ“ˆ LLY shares closed up 1.82% at $1,008.39, outperforming the S&P 500.

πŸ’° Analysts project quarterly EPS of $7.5 and revenue of $17.66 billion.

⚠️ Stock trades at a high Forward P/E of 29 vs industry average of 15.83.

πŸ“ˆ Eli Lilly shares closed up 1.82% at $1,008.39, outperforming the S&P 500's 0.83% gain.

πŸ“‰ Despite recent gains, LLY stock has depreciated 6.41% over the past month.

πŸ—“οΈ The company is scheduled to release its quarterly earnings report on April 30, 2026.

πŸ’° Analysts project upcoming quarterly EPS of $7.5, representing a 124.55% year-over-year increase.

πŸ’΅ Expected quarterly revenue is forecasted at $17.66 billion, up 38.75% from the prior quarter.

πŸ“Š Full-year earnings consensus estimates total $34.16 per share with a 41.1% year-over-year rise.

πŸ“‰ Full-year revenue is projected at $81.93 billion, marking a 25.7% increase from last year.

πŸ“‰ The Zacks Consensus EPS estimate has shifted 0.24% upward recently for the company.

βš–οΈ Eli Lilly currently holds a Zacks Rank of #3 (Hold) according to the investment model.

πŸ’° LLY trades at a Forward P/E ratio of 29, significantly higher than the industry average of 15.83.

πŸ“ˆ The stock's PEG ratio is 1.17, which is lower than the Large Cap Pharmaceuticals industry average of 2.24.

🏭 The company belongs to the Medical sector, specifically within the Large Cap Pharmaceuticals industry.

πŸ“‰ This industry group ranks #200 and sits in the bottom 19% echelon of all industries tracked.

πŸ“ˆ Top-rated industries historically outperform the bottom half by a factor of 2 to 1.

⚠️ Investors are advised to monitor analyst estimate revisions as they correlate with stock price performance.

Bullish Signals
  • Shares rose 1.82% to $1,008.39, outpacing S&P 500's 0.83% gain.
  • Analysts project 124.55% earnings growth with quarterly EPS of $7.5.
  • Full-year consensus EPS forecast reaches $34.16, up 41.1% from prior year.
  • Projected annual revenue hits $81.93 billion, a 25.7% increase.
  • PEG ratio of 1.17 is below industry average of 2.24, showing value.
  • Consensus EPS estimate increased 0.24% recently amid positive analyst adjustments.
Risk Factors
  • Shares down 6.41% this month, underperforming sector and index.
  • Forward P/E of 29 is near double the industry average of 15.83.
  • High P/E relative to peers creates valuation risk despite neutral PEG.
  • Zacks Rank #3 hold rating limits strong buy opportunity.
  • Pharma industry ranks bottom 19% among all 250+ sectors.
Bullish Signals
  • Eli Lilly shares were up +1.82% at $1,008.39, outpacing the S&P 500's daily gain of 0.83%.
  • Analysts expect year-over-year earnings growth of 124.55%, with quarterly EPS estimated at $7.5.
  • Full-year Zacks Consensus Estimates project earnings of $34.16 per share, representing a +41.1% change from the prior year.
  • The company's projected full-year revenue of $81.93 billion represents a +25.7% increase from the prior year.
  • Eli Lilly is currently trading with a PEG ratio of 1.17, which is significantly lower than the industry average of 2.24, indicating value relative to growth.
  • The Zacks Consensus EPS estimate has shifted 0.24% upward recently, reflecting positive adjustments in analyst expectations.
Risk Factors
  • Eli Lilly's shares have depreciated by 6.41% over the past month, underperforming both the Medical sector (down 3.46%) and the S&P 500 (down 2.65%), indicating relative weakness despite positive market movements.
  • The stock is trading at a Forward P/E ratio of 29 compared to the industry average of 15.83, suggesting it is valued at a significant premium that could limit upside potential.
  • Eli Lilly's PEG ratio stands at 1.17 versus an industry average of 2.24, though this metric alone is neutral; however, the high P/E relative to peers remains a valuation risk.
  • The stock currently holds a Zacks Rank of #3 (Hold), indicating the analysis does not rate it as a strong buy opportunity at this time.
  • The Large Cap Pharmaceuticals industry ranks in the bottom 19% echelons among all 250+ industries, with top-rated sectors historically outperforming by a factor of 2 to 1, suggesting potential sector headwinds.